Pharmaceutical Raw Materials

A finished pharmaceutical product and its active pharmaceutical ingredient, usually shortened to API, occupy different positions in medicine manufacturing. WHO maintains a separate API-prequalification procedure, demonstrating why an ingredient's quality and manufacturing history deserve examination independently of the finished medicine. An API master file documents manufacturing details and quality controls; WHO's procedure also verifies manufacturing-site compliance with good manufacturing practice. s1

This distinction is especially useful when reading about Iran's domestic medicine industry. A statement that a finished medicine is manufactured domestically does not, by itself, identify where its active ingredient or upstream materials originated. Establishing local ingredient capability requires evidence about the ingredient and manufacturing site, rather than an inference from the final product's label. This is an analytical distinction, not a quantified estimate of Iran's import dependence.

The International Council for Harmonisation's Q7 guideline, published by the European Medicines Agency, provides a useful international reference for API manufacturing. Its materials-management section calls for written procedures covering receipt, identification, quarantine, storage, sampling, testing, and approval or rejection. Critical-material suppliers should be evaluated, purchases should follow agreed specifications, and the actual manufacturer should be known when a trader supplies the material. s2

The guideline also treats a supplier's certificate of analysis as evidence that requires a supporting control system. It permits reliance on such certificates for certain tests under specified conditions, while requiring supplier evaluation and checks on certificate reliability. Changing the source of a critical raw material falls within change control. The practical lesson is that a familiar ingredient name or a trader's paperwork is not a substitute for knowing the manufacturer and the batch's documented quality history. These are international guidance principles; this page does not establish their implementation at individual Iranian sites. s2

A simplified materials-control sequence

The arrows show a simplified quality-control sequence drawn from ICH Q7, not the verified workflow of an Iranian factory or a complete manufacturing procedure.

An English-language Iranian development-plan extract hosted by WHO explicitly includes pharmaceutical raw materials within a pricing provision addressing subsidized or exclusive goods. This places upstream inputs within a broader policy discussion of medicine supply. The document describes policy requirements; it does not report ingredient output, supplier concentration, import shares, or the implementation of particular controls. Its precise legal standing and subsequent amendments require further verification. s3

A defensible assessment of Iran's raw-material sector must therefore separate ingredient manufacture from trade, and product availability from manufacturing capacity. Useful evidence would identify individual substances, production sites, quantities, reporting periods, and the scope of each quality authorization. Without those records, a national self-sufficiency percentage would conceal more than it explains. The available evidence supports this account of the quality and measurement questions, but not a comprehensive inventory of Iran's upstream pharmaceutical industry.